PL2769727T3 - Kombinacja deoksynukleozydu/nukleozydu do stosowania w leczeniu nowotworów - Google Patents
Kombinacja deoksynukleozydu/nukleozydu do stosowania w leczeniu nowotworówInfo
- Publication number
- PL2769727T3 PL2769727T3 PL12842329T PL12842329T PL2769727T3 PL 2769727 T3 PL2769727 T3 PL 2769727T3 PL 12842329 T PL12842329 T PL 12842329T PL 12842329 T PL12842329 T PL 12842329T PL 2769727 T3 PL2769727 T3 PL 2769727T3
- Authority
- PL
- Poland
- Prior art keywords
- deoxynucleoside
- tumors
- treatment
- nucleoside
- combination
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 239000002777 nucleoside Substances 0.000 title 1
- 150000003833 nucleoside derivatives Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011103143094A CN102499937A (zh) | 2011-03-02 | 2011-10-17 | 脱氧核苷与核苷组合在制备治疗肿瘤药物中的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2769727T3 true PL2769727T3 (pl) | 2017-01-31 |
Family
ID=48141653
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL12842329T PL2769727T3 (pl) | 2011-10-17 | 2012-10-16 | Kombinacja deoksynukleozydu/nukleozydu do stosowania w leczeniu nowotworów |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20140309188A1 (pl) |
| EP (1) | EP2769727B1 (pl) |
| CN (2) | CN102172359A (pl) |
| DK (1) | DK2769727T3 (pl) |
| ES (1) | ES2587850T3 (pl) |
| HU (1) | HUE029492T2 (pl) |
| PL (1) | PL2769727T3 (pl) |
| WO (1) | WO2013056510A1 (pl) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102172359A (zh) * | 2011-03-02 | 2011-09-07 | 张始状 | 腺苷与核苷组合在制备治疗肿瘤药物中的应用 |
| CN106074590A (zh) * | 2014-11-24 | 2016-11-09 | 张始状 | 脱氧嘌呤核苷与其它核苷或碱基组合制备的抗肿瘤药物及其制备方法和应用 |
| CN115068495B (zh) * | 2022-07-05 | 2023-08-18 | 四川大学华西医院 | 核苷单体在制备抗肿瘤的药物中的用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1941942A1 (de) * | 1969-08-18 | 1971-03-04 | Sylven Bengt Prof Dr | Neues pharmazeutisches Mittel |
| US5104859A (en) * | 1985-09-24 | 1992-04-14 | Solimedco Aktiebolag | Continuous administration of adenosine to reduce pulmonary vascular resistance |
| US5231086A (en) * | 1985-09-24 | 1993-07-27 | Item Development Aktiebolag | Continuous administration adenosine to increase myocardial blood flow |
| IL121272A (en) * | 1997-07-10 | 2000-06-01 | Can Fite Technologies Ltd | Pharmaceutical compositions comprising adenosine and their use for treating or preventing leukopenia |
| US20020006913A1 (en) * | 1997-11-04 | 2002-01-17 | Von Borstel Reid W. | Antimutagenic compositions for treatment and prevention of photodamage to skin |
| WO2005016455A2 (en) * | 2003-08-14 | 2005-02-24 | D. Collen Research Foundation Vzw | Antibodies against factor viii with modified glycosylation in the variable region |
| US6642211B2 (en) * | 2001-04-06 | 2003-11-04 | Wisconsin Alumni Research Foundation | Treatment of cancer with thymidine in combination with temozolamide |
| CA2526212C (en) * | 2003-05-16 | 2013-08-27 | Hybridon, Inc. | Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents |
| CN102172359A (zh) * | 2011-03-02 | 2011-09-07 | 张始状 | 腺苷与核苷组合在制备治疗肿瘤药物中的应用 |
-
2011
- 2011-03-02 CN CN2011100490469A patent/CN102172359A/zh active Pending
- 2011-10-17 CN CN2011103143094A patent/CN102499937A/zh active Pending
-
2012
- 2012-10-16 EP EP12842329.0A patent/EP2769727B1/en not_active Not-in-force
- 2012-10-16 DK DK12842329.0T patent/DK2769727T3/en active
- 2012-10-16 HU HUE12842329A patent/HUE029492T2/en unknown
- 2012-10-16 PL PL12842329T patent/PL2769727T3/pl unknown
- 2012-10-16 ES ES12842329.0T patent/ES2587850T3/es active Active
- 2012-10-16 WO PCT/CN2012/001392 patent/WO2013056510A1/zh not_active Ceased
-
2014
- 2014-04-17 US US14/254,911 patent/US20140309188A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2769727A4 (en) | 2014-09-17 |
| CN102499937A (zh) | 2012-06-20 |
| WO2013056510A1 (zh) | 2013-04-25 |
| DK2769727T3 (en) | 2016-08-29 |
| ES2587850T3 (es) | 2016-10-27 |
| CN102172359A (zh) | 2011-09-07 |
| HUE029492T2 (en) | 2017-02-28 |
| EP2769727B1 (en) | 2016-05-18 |
| EP2769727A1 (en) | 2014-08-27 |
| US20140309188A1 (en) | 2014-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB201115711D0 (en) | Phyto-cannabinoids for use in the treatment of cancer | |
| IL275874A (en) | Therapeutic use of adenovirus | |
| GB2495841B (en) | Phytocannabinoids for use in the treatment of breast cancer | |
| IL238400A0 (en) | Triazolopyrazines as brd4 inhibitors for use in cancer therapy | |
| ZA201207574B (en) | Phytocannabinoids in the treatment of cancer | |
| IL230698A0 (en) | Use of preparations containing crizotinib to treat cancer | |
| ZA201603332B (en) | Gla monotherapy for use in cancer treatment | |
| BR112014009755A2 (pt) | tratamento de câncer com inibidores de quinase tor | |
| IL235062A0 (en) | Compounds and methods for antiviral therapy | |
| SI2780332T1 (sl) | Morfolinilbenzotriazini za uporabo pri terapiji raka | |
| IL238116B (en) | A process for preparing compounds for use in the treatment of cancer | |
| SG10201702375RA (en) | Telomerase inhibitors for use in therapy | |
| PL2742356T3 (pl) | Środki prognostyczne w leczeniu nowotworów | |
| IL238453A0 (en) | Trans-clomiphene for use in cancer treatment | |
| GB2515440B (en) | Vesicular Formulations for use in the treatment of Rosacea | |
| ZA201307058B (en) | Use of polyaminoisoprenyl derrivatives in antobiotic or antisertic treatment | |
| SI2872176T1 (sl) | Karboranilporfirin za uporabo pri zdravljenju raka | |
| PL2769727T3 (pl) | Kombinacja deoksynukleozydu/nukleozydu do stosowania w leczeniu nowotworów | |
| IL225465A0 (en) | b or c polymorphs of picropodophyllin for use in cancer therapy | |
| PL3351104T3 (pl) | Związki do stosowania w leczeniu okresowych zaburzeń wybuchowych | |
| GB201718726D0 (en) | Phytocannabinoids in the treatment of cancer | |
| ZA201407164B (en) | Device for use in the treatment hyperbilirubinemia | |
| HUP1000688A2 (en) | Use of trifluoro-phthalimides in the treatment of cancer | |
| GB201208770D0 (en) | Compounds for use in the treatment of adenovirus infections |